TuHURA Reports Partial Responses in First Three Patients in IFx-2.0–Keytruda Merkel Cell Carcinoma Trial

• TuHURA Biosciences on October 26, 2026, reported preliminary results from its Phase 1b/2a trial of IFx-2.0 with Keytruda for metastatic Merkel cell carcinoma.
• All three initial patients experienced substantial tumor shrinkage, with responses ongoing at six months.
• The nine-patient study evaluates safety and feasibility in patients with deep-seated or bulky tumors receiving first-line treatment.
• Continued strong responses could prompt trial expansion and FDA discussions about supplementing the ongoing Phase 3 trial, contingent on its success.
• Results have been disclosed; presentation at a scientific conference is planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260730PR_NEWS_USPR_____LA80464) on October 26, 2026, and is solely responsible for the information contained therein.